Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions
A legfontosabb adatok
- Ki végzi
- Barinthus Biotherapeutics
- Hol
- Belgium, Egyesült Királyság és Észtország16 helyszín, 3 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 1/2. fázis
- Résztvevők
- 108 fő vett részt
- Kezdés
- 2021. márc. 16.
- Befejezés
- 2024. jan. 16.
- A vizsgálat típusa
- Beavatkozással járó, 9 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- ChAdOx1-HPV
- MVA-HPV
- Placebo
- A regiszteradat frissítve
- 2025. augusztus 28.
Ki vehet részt
- Életkor
- 25 év – 55 év
- Nem
- Csak nők
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter összes feltétele (18)A regiszter feltételeinek elrejtése
Ki vehet részt
- Females aged ≥25 and ≤55 years of age at screening
- Persistent hrHPV infection defined as a documented cervical infection with hrHPV type(s) in the 6 to 18 months prior to screening and confirmed at screening (participants in the main and expansion phases only). Participants in the lead-in phase are only required to have the screening result
- Low- grade cervical lesion (CIN1 or HPV-related change only) confirmed by histology and/or cytology report within the 1 year prior to screening
- Not pregnant or breast feeding and one of the following:; Of non-childbearing potential (i.e. women who have had a hysterectomy or tubal ligation or are postmenopausal, as defined by no menses for at least 12 months and without an alternative medical cause); Of childbearing potential but agrees to practice highly effective contraception for 4 weeks prior to administration of the first dose of study vaccine and throughout the study until 8 weeks after administration of the second dose. Highly effective methods of contraception include one or more of the following:; Male partner who is sterile (medically effective vasectomy) prior to the female participant's entry into the study and is the sole sexual partner for the female participant; Hormonal (oral, intravaginal, transdermal, implantable or injectable). Progestogen-only hormonal contraceptives without inhibition of ovulation are not considered to be highly effective; An intrauterine hormone releasing system; An intrauterine device; Bilateral tubal occlusion; Sexual abstinence, only if the participant refrains from heterosexual intercourse during the entire study period and it is the usual lifestyle of the participant
- Willing to abstain from sexual activity for 48 hours prior to all swabbing procedures
Ki nem vehet részt
- Evidence of high grade cervical lesions by colposcopy or by Papanicolaou (Pap) smear test in the 1 year prior to screening
- Receipt of any investigational drug or investigational vaccine within 3 months prior to administration of ChAdOx1-HPV on Day 0, or prior participation in a clinical study of any HPV vaccine
- Receipt of any adenoviral based vaccine within 3 months prior to administration of ChAdOx1 HPV on Day 0, or plan to receive an adenoviral-based vaccine within 3 months after Day 0
- Receipt of any live vaccines within the 30 days or inactivated vaccine within the 14 days prior to administration of ChAdOx1-HPV on Day 0 or planned to occur in the 2 months after the Day 0 vaccination
- Current or history of illicit drug use within the 6 months prior to screening
- Current or history of severe alcohol abuse within the 6 months prior to screening
- Presence of any significant acute or chronic, uncontrolled medical (or psychiatric) illness, including blood dyscrasias
- Immunosuppression as a result of underlying illness or treatment including:; Use of high dose corticosteroids ( >10 mg/day prednisone or equivalent) for ≥7 days (inhaled, otic and ophthalmic corticosteroids are permitted); Primary immune deficiency disease; Use of synthetic or biologic disease-modifying antirheumatic drugs; History of bone marrow or solid organ transplant; History of any other clinically significant autoimmune or immunosuppressive disease
- Positive diagnostic tests (for human immunodeficiency virus, hepatitis B or hepatitis C) indicating chronic infection
- Any history of anaphylaxis in reaction to vaccination or history of allergic reactions likely to be exacerbated by any component of the vaccine, e.g. severe allergy to eggs
- Current known infection with severe acute respiratory syndrome coronavirus 2 (SARS CoV-2)
- Any laboratory test which is abnormal and deemed by the Investigator to be clinically significant which will potentially affect the participation in the study
- Any other finding that, in the opinion of the Investigator, deems the participant unsuitable for the study
Hol van ez a vizsgálat?
3 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
A Phase 1b/2 multi-centre study evaluating the safety, efficacy and immunogenicity of prime-boost vaccines ChAdOx1-HPV and MVA-HPV in women with HPV related low grade cervical lesions.
A vizsgálat 9 csoportja
- Lead-in Group A ChAdOx1-HPV low dose and MVA-HPV low doseA vizsgált kezelés
Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^8 vp) and MVA-HPV (1 x 10\^7 pfu)
Kezelés: ChAdOx1-HPV és MVA-HPV
- Lead-in Group B ChAdOx1-HPV mid dose and MVA-HPV low doseA vizsgált kezelés
Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^9 vp) and MVA-HPV (1 x 10\^7 pfu)
Kezelés: ChAdOx1-HPV és MVA-HPV
- Lead-in Group C ChAdOx1-HPV high dose and MVA-HPV high doseA vizsgált kezelés
Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^10) vp and MVA-HPV (1 x 10\^8 pfu)
Kezelés: ChAdOx1-HPV és MVA-HPV
- Group 1 ChAdOx1-HPV mid dose and MVA-HPV low doseA vizsgált kezelés
Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^9 vp) and MVA-HPV (1 x 10\^7 pfu)
Kezelés: ChAdOx1-HPV és MVA-HPV
- Group 2 ChAdOx1-HPV high dose and MVA-HPV low doseA vizsgált kezelés
Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^10 vp) and MVA-HPV (1 x 10\^7 pfu)
Kezelés: ChAdOx1-HPV és MVA-HPV
- Group 3 ChAdOx1-HPV low dose and MVA-HPV high doseA vizsgált kezelés
Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^8 vp) and MVA-HPV (1 x 10\^8 pfu)
Kezelés: ChAdOx1-HPV és MVA-HPV
- Group 4 ChAdOx1-HPV mid dose and MVA-HPV high doseA vizsgált kezelés
Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^9 vp) and MVA-HPV (1 x 10\^8 pfu)
Kezelés: ChAdOx1-HPV és MVA-HPV
- Group 5 ChAdOx1-HPV high dose and MVA-HPV high doseA vizsgált kezelés
Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^10 vp) and MVA-HPV (1 x 10\^8 pfu)
Kezelés: ChAdOx1-HPV és MVA-HPV
- Group 6 Placebo SalinePlacebo, összehasonlításként
Sodium Chloride (0.9%)
Kezelés: Placebo
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase 1b/2, Randomised, Placebo-controlled, Dose-ranging Study to Evaluate Safety, Tolerability and Immunogenicity of a Chimpanzee Adenovirus (ChAdOx1)-Vectored Multigenotype High Risk Human Papillomavirus (hrHPV) Vaccine and Modified Vaccinia Ankara (MVA)-Vectored Multigenotype hrHPV Vaccine in Women With Low-grade HPV-related Cervical Lesions
- Publikációk
- A Phase 1b/2, Randomised, Placebo-controlled Study to Evaluate Safety, Tolerability, Efficacy, and Immunogenicity of VTP-200, a Chimpanzee Adenovirus and Modified Vaccinia Ankara-vectored Multigenotype High-risk Human Papillomavirus Vaccine in Women With Low-grade Cervical Lesions.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026
- A regiszteradat frissítve
- 2025. augusztus 28.